Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Pomalidomide
Related studies linked through entity extraction aliases.
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE3
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
- Status
- COMPLETED
- Phase
- PHASE2
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
- Status
- TERMINATED
- Phase
- PHASE3
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
- Status
- COMPLETED
- Phase
- N/A
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1